Driven by growing market demand and an improving supply chain, the global weight-loss drug market is expected to hit $150 ...

For the past year and a half, Tandra Cooper Harris and her husband, Marcus, who both have diabetes, have struggled to fill ...

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic ...

The benefit-harm balance of initiating Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) versus a placebo intervention.

ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in ...

Altimmune is developing pemvidutide, a dual agonist of GLP-1 and glucagon receptors, with promising phase 2 data already seen ...

Image Credit: luchschenF/Shutterstock.com Semaglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1RA) ...